Characteristics of the study population at the time of entry into the observational period
| Previous cancer (n=405) | No previous cancer (n=16 642) | All (n=17 047) | |
|---|---|---|---|
| Age, years, mean (SD) | 56.3 (14.4) | 39.8 (15.4) | 40.2 (25.6) |
| Male gender, n (%) | 196 (48.4) | 7488 (45.0) | 7684 (45.1) |
| Duration of disease, years, mean (SD) | 13.5 (10.7) | 8.2 (7.9) | 8.3 (8.0) |
| IBD subtype, n (%) | |||
| Crohn's disease | 211 (52.1) | 10 192 (61.2) | 10 403 (61.0) |
| Ulcerative colitis or IBD, unclassified | 194 (47.9) | 6450 (38.8) | 6644 (39.0) |
| Thiopurines | |||
| Continuing | 77 (19.0) | 5263 (31.6) | 5340 (31.3) |
| Discontinued | 68 (16.8) | 2436 (14.6) | 2504 (14.7) |
| Never received | 260 (64.2) | 8943 (53.7) | 9203 (54.0) |
| Methotrexate | |||
| Continuing | 10 (2.5) | 616 (3.7) | 626 (3.7) |
| Discontinued | 10 (2.5) | 628 (3.8) | 638 (3.7) |
| Never received | 385 (95.0) | 15 398 (92.5) | 15 783 (92.6) |
| Anti-TNF therapy | |||
| Continuing | 7 (1.7) | 839 (5.0) | 846 (5.0) |
| Discontinued | 13 (3.2) | 928 (5.6) | 941 (5.5) |
| Never received | 385 (95.1) | 14 875 (89.4) | 15 260 (89.5) |
| Other immunosuppressant | |||
| Continuing | 4 (1.0) | 133 (1.1) | 177 (1.0) |
| Discontinued | 7 (1.7) | 437 (2.6) | 444 (2.6) |
| Never received | 394 (97.3) | 16 032 (96.3) | 16 426 (96.4) |
| Follow-up, patient-years, n | 1091 | 48 328 | 49 419 |